BIOCYTOGEN
3.1.2023 15:24:36 CET | Business Wire | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SEHK : 02315) a clinical-stage biotechnology company with a focus on the antibody discovery and development based on its proprietary RenMiceTM Platforms, and Hansoh Pharmaceutical Group Company Limited (“Hansoh Pharma”, SEHK: 3692), a leading innovation-driven pharmaceutical company with a focus on the treatment of major diseases including oncology, infectious diseases, CNS disorders, metabolic diseases and autoimmune diseases, today announced an antibody collaboration, assignment and exclusive license agreement. Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules against the designated target for the development, manufacturing and commercialization globally. Under the agreement, Biocytogen will receive an upfront payment and will be eligible to receive development and commercial milestones of up to tens of millions of Chinese yuan, as well as single-digit tiered royalties on net sales.
“We are very excited to partner with Hansoh Pharma, one of the largest pharmaceutical companies in China. The licensed antibodies were selected from Biocytogen’s Project Integrum programs and generated from our proprietary fully human antibody RenMiceTM target-knockout mice. The antibodies possess highest possible diversity to improve the success rate of antibody discovery,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “Thanks to Hansoh Pharma’s recognition of our RenMiceTM platforms and Project Integrum. We believe Hansoh Pharma’s strong R&D, manufacturing and commercialization capabilities will accelerate the development of RenMiceTM-derived antibody molecules and bring the benefits to patients worldwide.”
About Project Integrum
Project Integrum is a large-scale antibody drug development project for 1000+ potential drug targets using RenMiceTM (RenMabTM, RenLite® and RenNano®) target knockout mice. Different from the traditional mechanism of action (MOA)-based drug development strategy, Project Integrum uses large-scale in vivo drug efficacy screening methods to discover innovative drugs with excellent safety and efficacy. So far, we have completed making RenMiceTM KO for 1000+ targets. In addition, we have developed a large variety of preclinical antibody assets including 10 fully human bispecific antibodies, 20+ bispecific ADCs, 10+ TCR-mimic antibodies, 30+ monoclonal antibodies against novel targets, and 600+ antibody hits. Antibody molecules generated by Project Integrum have high specificity, high affinity and good druggability, which have attracted many top biopharmaceutical companies to obtain a license or reach a drug co-development agreement with us, including Merck KGaA, ADC Therapeutics, Remgen, NJCTTQ, etc.
About Biocytogen
Biocytogen (HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM/RenLite®/RenNano® mice platforms for fully human monoclonal, bispecific/multispecific antibody and nanobody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop first-in-class and/or best-in-class antibody drugs for more than 1000 targets, known as Project Integrum. This project has resulted in 28 drug co-development agreements and 16 RenMiceTM licensing agreements with companies around the world, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai, Boston, USA and Heidelberg, Germany. For more information, please visit http://en.biocytogen.com.cn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230103005498/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rubrik Security Cloud Launches on the AWS European Sovereign Cloud8.7.2026 09:00:00 CEST | Press release
The launch will allow highly regulated European Union organisations to meet strict EU data residency requirements Rubrik, the Security and AI Operations Company, today announced the availability of Rubrik Security Cloud on the AWS European Sovereign Cloud, providing the European Union (EU) public sector and highly regulated private organisations with a cloud-native path for sovereign cyber resilience. Organisations increasingly require resilience measures that are sovereign, not just contractually compliant. Rubrik Security Cloud on the AWS European Sovereign Cloud meets this demand. It will allow highly regulated industries, such as banking, utilities, healthcare, and government, to leverage the full power of AWS, while meeting stringent data residency requirements within the European Union (EU). Advanced security features on a fully featured, independently operated sovereign cloud The AWS European Sovereign Cloud is a fully featured, independently operated sovereign cloud backed by s
Wolters Kluwer Brings Libra AI Workflows Into One for Italian Legal Professionals8.7.2026 09:00:00 CEST | Press release
Building on Libra by Wolters Kluwer’s early leadership, strong market momentum and advanced AI innovation in Italy, its capabilities are now directly available in One via the Libra add-in. Wolters Kluwer Legal & Regulatory today announced the integration of Libra by Wolters Kluwer AI workflows in One, its leading legal research platform in Italy. This step further reinforces the strong commercial success and rapid market adoption of the Libra legal AI workspace in the country. With the integration generative AI features are directly available in the research workflow of legal professionals allowing a seamless experience without switching between tools. The integration follows the launch of the Libra legal AI workspace in Italy in February, setting a new benchmark for AI-enabled legal research by combining advanced AI capabilities with authoritative and trusted legal content from One and supporting lawyers across their full workflow, from research to analysis and document drafting. With
Flix and Klarna Expand Partnership to Give Millions of Travelers Across the U.S. and Europe More Ways to Pay8.7.2026 09:00:00 CEST | Press release
Flix and Klarna, the global digital bank and flexible payments provider, today announced an expanded partnership that brings more flexible payment options to millions of travelers across its platforms. Beginning today, Klarna will be available in 21 Flix markets, adding the UK, Germany, Italy, France, Poland, Switzerland, Austria, and Spain, among others, to its existing presence in the U.S. and Sweden. With Klarna now embedded directly into the Flix booking flow, passengers have three new ways to pay: in full at the time of booking, in interest-free installments, or through longer-term financing for larger purchases. For cross-border journeys, Klarna removes foreign exchange fees, letting travelers pay in their local currency with no hidden conversion costs. Klarna users will also receive exclusive deals when booking through Flix platforms. "Travel is one of the biggest spending categories in people's lives, yet flexibility at checkout has lagged behind,” said David Sykes, Chief Comme
Record Launches "Record Amanah" Sharia-Compliant Investment Platform8.7.2026 09:00:00 CEST | Press release
Record Asset Management GmbH (RAM), subsidiary of London-listed Record plc (Record Financial Group), is pleased to announce the launch of Record Amanah, its dedicated platform for Sharia-compliant investment solutions. RAM is the European asset management arm of Record Financial Group, the London-listed specialist investment group managing USD 115 billion of assets on behalf of institutional clients worldwide. Record's client base comprises pension funds, foundations, sovereign institutions and other asset managers, with whom the Group has built long-standing relationships through its focus on bespoke investment and risk management solutions. Headquartered in London, Record has offices in Hamburg, Zurich, Zug, New York, and Hong Kong. The launch follows a series of successful Sharia-compliant transactions completed by Record, most recently for a client in Brunei, and reflects growing demand from institutional investors seeking investment opportunities that combine attractive risk-adjus
Axelspace’s Seven GRUS-3 Earth Observation Microsatellites Successfully Launched and First Signals Received8.7.2026 07:00:00 CEST | Press release
Axelspace Corporation (“Axelspace”), a leading developer and operator of microsatellites dedicated to realizing its vision of “Space within Your Reach,” announced that the seven GRUS-3 next-generation Earth observation microsatellites were successfully launched and that the first radio signals were successfully received. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260707291751/en/ The successful launch of Falcon 9 ©SpaceX GRUS-3 was integrated via Exolaunch and launched aboard a SpaceX Falcon 9 rocket from Vandenberg Space Force Base in California, USA, on July 7, 2026 at 07:12 (UTC) during the Transporter-17 rideshare mission. The satellites were successfully put into their intended orbit. Axelspace received the first radio signals from all the seven satellites in orbit. The satellites are currently operating normally. Axelspace is working toward completing the critical operation of the GRUS-3 microsatellite to ensure pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom